The sensor to participate in the 2nd Annual LifeSci Partners Genetics Symposium on June 29, 2022

Montpellier, France, June 24, 2022– (work wire) – Regulatory information:

Sensors (FR0012596468 – ALSEN) (Paris:ALSEN) A number one clinical-stage biotechnology firm that focuses on creating novel therapies for the restoration, remedy, and prevention of listening to loss issues, is happy to announce the participation of Nawal Ozern, CEO of LifeSci Companions 2.second abbreviation The Annual Symposium on Genetic Medicines takes place roughly 28-29 June 2022.

CEO Nawal Ozren will share a chat with Jeff Goodenburg as a part of LifeSci Companions 2second abbreviation Annual Symposium on Genetic Medicineson June 29, 2022. To attend the dialogue, please register over right here. A replay of the facet chat can be accessible shortly after the presentation ends on the similar time Hyperlink.

Date: Wednesday 29 June 2022
subsequent to the fireside chat: 8.30 a.m. – 9 a.m. EST (2.30 p.m. – 3 p.m. CST)
OccasionLifeSci 2 . Companionssecond abbreviation Annual Symposium on Genetic Medicines

About Sensor

Sensorion is a number one clinical-stage biotechnology firm that focuses on creating new therapies to revive, deal with and stop listening to loss issues, a big unmet world medical want.

Sensorion has constructed a novel analysis and growth know-how platform to develop its understanding of the pathophysiology and pathogenesis of the inside ear, enabling it to pick one of the best targets and strategies for drug candidates. Her portfolio combines small molecule applications with a preclinical portfolio of inside ear genetic therapies.

Its medical section portfolio consists of one Section II product: SENS-401 (Arazasetron) advancing in a deliberate Section II medical examine of the idea of SENS-401 in cisplatin-induced ototoxicity (CIO) and with accomplice Cochlear Restricted, a examine of SENS-401 in Sufferers scheduled for cochlear implantation.

Sensorion has entered right into a broad strategic collaboration with the Pasteur Institute specializing in the genetics of audiology. It accommodates two gene remedy applications aimed toward correcting single-gene genetic types of deafness together with deafness brought on by a mutation within the gene coding for Otoferlin, and listening to loss related to a mutation within the GJB2 gene to handle necessary listening to loss segments in adults and kids. The corporate can also be working to establish biomarkers to enhance the prognosis of those underserved ailments.

www.sensorion.com

a poster: sensor
inside: FR0012596468
mnemonic: ALSEEN

disclaimer

This press launch accommodates sure forward-looking statements concerning Sensorion and its enterprise. These forward-looking statements are based mostly on assumptions that Sensorion considers cheap. Nonetheless, there may be no assure that these forward-looking statements can be verified, that are topic to quite a few dangers, together with these set forth within the Full 12 months 2021 Monetary Report printed on April 28, 2022 accessible on our web site and to creating financial circumstances. and the monetary markets and markets by which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers that aren’t but recognized to Sensorion or not presently thought of by Sensorion. The incidence of all or a part of these dangers may trigger Sensorion’s precise outcomes, monetary circumstances, efficiency or achievements to be materially totally different from such forward-looking statements. This press launch and the data it accommodates don’t represent a proposal to promote or subscribe or a solicitation of a proposal to purchase or subscribe for the shares of Sensorion in any nation. Relaying this press launch in some nations could represent a violation of native legal guidelines and laws. Any recipient of this press launch should inform themselves of and adjust to any such native restrictions.

View the supply model on businesswire.com: https://www.businesswire.com/information/house/20220623005695/ar/

Contacts

Investor Relations
Catherine Levo
Head of Investor Relations and Communication
+33 6 72 18 00 22
ir.contact@sensorion-pharma.com

Worldwide Media Relations
Consilium Strategic Communications
Mary Jane Elliott / Jessica Hodgson
+44 7739 788014
+44 7561 424788
Sensorion@consilium-comms.com